Annual report [Section 13 and 15(d), not S-K Item 405]

OPERATING SEGMENT (Details)

v3.25.0.1
OPERATING SEGMENT (Details)
12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
SEGMENT INFORMATION    
Number of operating segments | segment 1  
Number of Reportable Segments | segment 1  
Research and development    
General and administrative $ 25,641,452 $ 11,694,367
Segment and consolidated net loss 44,581,446 42,770,610
Single reportable segment    
Research and development    
Phase 2 study in WM 7,422,000 12,652,000
Phase 1 study in pediatric tumors 3,040,000 2,480,000
Manufacturing and related costs 10,582,000 9,341,000
Pre-clinical projects costs 228,000 483,000
General research and development costs 4,864,000 2,310,000
General and administrative 25,641,000 11,694,000
Other segment items 7,196,000 (3,811,000)
Segment and consolidated net loss $ 44,581,000 $ 42,771,000
Other segment items, description Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income.